Fuse your mitochondria, lose appetite: an anorexic, anti‐obesity sphingolipid
| Autor: | Carolin Muley, Alexander Bartelt |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Medicine (General)
medicine.medical_specialty media_common.quotation_subject Saturated fat QH426-470 Mitochondrion 03 medical and health sciences chemistry.chemical_compound R5-920 0302 clinical medicine Insulin resistance Internal medicine Genetics medicine 030304 developmental biology media_common 2. Zero hunger chemistry.chemical_classification 0303 health sciences Sphingosine Chemistry Fatty acid Appetite medicine.disease Sphingolipid 3. Good health Endocrinology Lipotoxicity Molecular Medicine 030217 neurology & neurosurgery |
| Zdroj: | EMBO Mol. Med.:e14618 (2021) EMBO Molecular Medicine, Vol 13, Iss 8, Pp n/a-n/a (2021) EMBO Molecular Medicine |
| ISSN: | 1757-4684 1757-4676 |
| DOI: | 10.15252/emmm.202114618 |
| Popis: | Aberrant production of ceramides, the precursors of complex sphingolipids, is a hallmark of obesity and strongly linked to metabolic dysfunction (Meikle and Summers 2017). Ceramides are formed by recycling or de novo synthesis from sphingosine and a fatty acid side chain moiety. The side chain length determines lipotoxicity of ceramides, as those composed of C16:0 or C18:0 side chains are toxic whereas those with C24:0 or C24:1 are not (Meikle and Summers 2017). Counteracting the deleterious effects of high‐fat diets (HFDs) rich in saturated fat either by inhibiting synthesis or by promoting degradation of ceramides mitigates insulin resistance and ectopic lipid accumulation (Meikle and Summers 2017). However, drugs that safely and selectively target ceramide metabolism have failed to translate into metabolic benefit in human trials so far. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|